Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Reports summarize cancer gene therapy research from University of Michigan, Medical Department
June 24th, 2008
"In this report, we developed a chimeric receptor ( N29 gamma chR) involving the single chain Fv ( scFv) derived from N29 monoclonal antibody ( mAb) specific for p185HER2 and characterized the therapeutic efficacy of primary T cells engineered to express N29g chR in two histologically distinct murine tumor models. Murine breast ( MT901) and fibrosarcoma ( MCA207) cancer cell lines were engineered to express human HER2 as targets," scientists in the United States report. "Administration of N29 gamma chR-expressing T cells eliminated 3-day pulmonary micrometastases of MT901/ HER2 and MCA207/ HER2 but not parental tumor cells. A 5 to 8-fold increased dose of N29g T cells...
Source: Cancer Weekly (2008-06-24)
|
